Veppanu-Vepdegestrant
Veppanu (vepdegestrant) is a new oral targeted therapy approved for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer or metastatic breast cancer after progression on prior endocrine therapy. Veppanu is a first-in-class PROTAC estrogen receptor degrader that selectively degrades the estrogen receptor, a critical driver of tumor growth and endocrine resistance in […]
Beqalzi-Sonrotoclax
Beqalzi (sonrotoclax) is an oral BCL-2 inhibitor indicated to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received prior therapies, including a BTK inhibitor. Beqalzi targets the BCL-2 protein, which prevents cells from dying in a programmed fashion, and helps control disease progression in patients with advanced hematologic malignancies. Beqalzi […]
Baxfendy-Baxdrostat
Baxfendy (baxdrostat) is a first-in-class oral therapy approved for adults with uncontrolled hypertension and resistant high blood pressure. The drug selectively inhibits aldosterone synthase, reducing excess aldosterone production, a key factor associated with persistent hypertension and increased cardiovascular risk. By targeting a hormonal pathway often overlooked by conventional blood pressure medications, Baxfendy introduces a new […]
Zaynich-Cefepime-And-Zidebactam
Zaynich (cefepime-zidebactam) is a novel antibacterial therapy for complicated urinary tract infections (cUTI) and serious infections caused by multidrug-resistant Gram-negative bacteria. The cefepime/zidebactam combination is designed to overcome resistance mechanisms and restore antibiotic activity against difficult-to-treat pathogens. Antimicrobial resistance remains a challenge to healthcare systems globally, and Zaynich offers an important new option for the […]
Xocova-Ensitrelvir
Xocova (ensitrelvir) is an oral antiviral indicated for the prevention and treatment of COVID-19 due to SARS-CoV-2 infection. Xocova selectively inhibits the 3CL protease, blocking this essential viral enzyme required for replication, helping to reduce viral load and limit disease progression. This therapy is a significant advance in the treatment of COVID-19 with an easy-to-take […]
Idvynso-Doravirine And Islatravir
Idvynso is a prescription oral therapy indicated as a complete regimen for the treatment of HIV-1 infection in adults who are already virologically suppressed on a stable antiretroviral regimen. Designed to replace an existing treatment in patients with no history of virologic failure and no known resistance to Doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor […]
Foundayo-Orforglipron
Foundayo is an oral, once-daily, investigational GLP-1 receptor pathway targeting therapy for chronic weight management in adults with obesity. Unlike injectable GLP-1 receptor agonists, orforglipron is a small-molecule, non-peptide option designed for convenient administration without food or water restrictions. Its mechanism focuses on appetite regulation, increased satiety, and reduced caloric intake, addressing key biological drivers […]
Icotyde-Icotrokinra Hydrochloride
Icotyde is a prescription medication indicated for the treatment of moderate-to-severe plaque psoriasis in patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Unlike topical treatments, Icotyde is intended for patients requiring systemic intervention, helping manage widespread or treatment-resistant disease. It works by […]
Lynavoy-Linerixibat
Lynavoy (linerixibat) is a prescription medication used in adults to treat cholestatic pruritus associated with primary biliary cholangitis (PBC), a chronic liver disease marked by bile acid buildup and persistent itching. Unlike conventional symptomatic treatments, Lynavoy works by inhibiting the ileal bile acid transporter (IBAT) in the intestine, reducing bile acid reabsorption and promoting their […]
Lifyorli-Relacorilant
Lifyorli (relacorilant) is a prescription medication used in combination with chemotherapy to treat advanced ovarian, fallopian tube, or primary peritoneal cancer in adults who have undergone prior treatments. Unlike conventional therapies, Lifyorli works as a selective glucocorticoid receptor antagonist, helping reduce tumor resistance and enhancing the effectiveness of chemotherapy. Advanced cancers often present challenges such […]
